Skip to main content
Fachgebiete
Automobil + Motoren Bauwesen + Immobilien Business IT + Informatik Elektrotechnik + Elektronik Energie + Nachhaltigkeit Finance + Banking Management + Führung Marketing + Vertrieb Maschinenbau + Werkstoffe Versicherung + Risiko
DE
EN
Themenseiten
Organisationspsychologie Projektmanagement Marketing Smart Manufacturing
Bücher
Zeitschriften
Weitere Formate
Podcasts Webinare Technik Webinare Wirtschaft Kongresse Veranstaltungskalender Awards
Jetzt Einzelzugang starten
Zugang für Unternehmen
Referenzkunden
MTZ-Fachkongress

Antriebe und Energiesysteme von morgen


Austausch von Automobil- und Energiewirtschaft

Am 14./15. Mai geht es in Chemnitz um die Mobilitätswende durch Elektro- und Wasserstofffahrzeuge.
Erweiterte Suche
Anmelden
nach oben
Erschienen in:
Industrial Challenges of Recombinant Proteins Kapitel lesen Erstes Kapitel lesen

2020 | OriginalPaper | Buchkapitel

Cytokines and Growth Factors

verfasst von : A. C. Silva, J. M. Sousa Lobo

Erschienen in: Current Applications of Pharmaceutical Biotechnology

Verlag: Springer International Publishing

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config
loading …

Abstract

Several cytokines have been used to treat autoimmune diseases, viral infections, and cancer and to regenerate the skin. In particular, interferons (INFs) have been used to treat cancer, hepatitis B and C, and multiple sclerosis, while interleukins (ILs) and tumor necrosis factors (TNFs) have been used in the management of different types of cancer. Concerning the hematopoietic growth factors (HGFs), epoetin has been used for anemia, whereas the colony-stimulating factors (CSFs) have been used for neutropenia. Other growth factors have been extensively explored, although most still need to demonstrate in vivo clinical relevance before reaching the market.
This chapter provides an overview on the therapeutic applications of biological medicines containing recombinant cytokines and growth factors (HGFs and others). From this review, we concluded that the clinical relevance of recombinant cytokines has been increasing. Since the 1980s, the European Medicines Agency (EMA) and/or Food and Drug Administration (FDA) have approved 89 biological medicines containing recombinant cytokines. Among these, 18 were withdrawn, 24 are biosimilars, and 18 are orphans.
So far, considerable progress has been made in discovering new cytokines, additional cytokine functions, and how they interfere with human diseases. Future prospects include the approval of more biological and biosimilar medicines for different therapeutic applications.

Graphical Abstract

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

  • über 102.000 Bücher
  • über 537 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Maschinenbau + Werkstoffe
  • Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 390 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Maschinenbau + Werkstoffe




 

Jetzt Wissensvorsprung sichern!

Jetzt informieren
Vorheriges Kapitel Therapeutic Antibody Engineering and Selection Strategies
Nächstes Kapitel Hormones, Blood Products, and Therapeutic Enzymes
Literatur
1.
Chen Y-C, Yeh M-K (2018) Introductory chapter: biopharmaceuticals. In: Chen Y-C, Yeh M-K (eds) Biopharmaceuticals. IntechOpen, London
2.
Walsh G (2013) Pharmaceutical biotechnology: concepts and applications. Wiley, Hoboken
3.
4.
5.
6.
7.
8.
Santos SB, Lobo JMS, Silva AC (2019) Biosimilar medicines used for cancer therapy in Europe: a review. Drug Discov Today 24(1):293–299PubMedCrossRef
9.
Silk AW, Margolin K (2019) Cytokine therapy. Hematol Oncol Clin 33:261–274CrossRef
10.
O’Shea JJ, Gadina M, Siegel RM (2019) 9 – Cytokines and cytokine receptors. In: Rich RR, Fleisher TA, Shearer WT, Schroeder HW, Frew AJ, Weyand CM (eds) Clinical immunology5th edn. Elsevier, London, pp 127–55.e1
11.
Lipiäinen T, Peltoniemi M, Sarkhel S, Yrjönen T, Vuorela H, Urtti A et al (2015) Formulation and stability of cytokine therapeutics. J Pharm Sci 104(2):307–326PubMedCrossRef
12.
13.
Moorkens E, Meuwissen N, Huys I, Declerck P, Vulto AG, Simoens S (2017) The market of biopharmaceutical medicines: a snapshot of a diverse industrial landscape. Front Pharmacol 8:314PubMedPubMedCentralCrossRef
14.
Crommelin DJA, Sindelar RD, Meibohm B (2013) Pharmaceutical biotechnology fundamentals and applications. Taylor & Francis, Milton ParkCrossRef
15.
Ryff J-C, Bordens RW, Pestka S (2013) Interferons and interleukins. In: Crommelin DJA, Sindelar RD, Meibohm B (eds) Pharmaceutical biotechnology: fundamentals and applications. Interferons and interleukins, vol 3 edn. Informa Healthcare, New York
16.
17.
18.
19.
20.
FDA (2008) ROFERON®-A: Interferon alfa-2a, recombinant
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
National Health Service (NHS) (2018) E. clinical commissioning policy: anakinra to treat periodic fevers and autoinflammatory diseases (all ages)
31.
National Health Service (NHS) (2018) E. clinical commissioning policy: anakinra/tocilizumab for the treatment of adult-onset Still’s disease refractory to second-line therapy (adults)
32.
33.
34.
35.
EMA (2015) Public summary of opinion on orphan designation: recombinant human interleukin-3 truncated diphtheria toxin fusion protein for the treatment of acute myeloid leukaemia
36.
37.
38.
39.
40.
41.
42.
43.
44.
Brar K, Leung DYM (2016) Recent considerations in the use of recombinant interferon gamma for biological therapy of atopic dermatitis. Expert Opin Biol Ther 16(4):507–514PubMedPubMedCentralCrossRef
45.
Mufarrege EF, Haile LA, Etcheverrigaray M, Verthelyi DI (2019) Multiplexed gene expression as a characterization of bioactivity for interferon beta (IFN-β) biosimilar candidates: impact of innate immune response modulating impurities (IIRMIs). AAPS J 21(2):26PubMedCrossRef
46.
Asadullah K, Sterry W, Trefzer U (2002) Cytokines: interleukin and interferon therapy in dermatology. Clin Exp Dermatol 27(7):578–584PubMedCrossRef
47.
Steen-Louws C, Hartgring SAY, Popov-Celeketic J, Lopes AP, de Smet MBM, Eijkelkamp N et al (2019) IL4-10 fusion protein: a novel immunoregulatory drug combining activities of interleukin 4 and interleukin 10. Clin Exp Immunol 195(1):1–9PubMedCrossRef
48.
49.
Tang K-Y, Lickliter J, Huang Z-H, Xian Z-S, Chen H-Y, Huang C et al (2019) Safety, pharmacokinetics, and biomarkers of F-652, a recombinant human interleukin-22 dimer, in healthy subjects. Cell Mol Immunol 16:473–482PubMedCrossRef
50.
Zhang H, Wang Y, Hwang ES, He Y-W (2016) Interleukin-10: an immune-activating cytokine in cancer immunotherapy. J Clin Oncol 34(29):3576–3578PubMedCrossRef
51.
Naing A, Papadopoulos KP, Autio KA, Ott PA, Patel MR, Wong DJ et al (2016) Safety, antitumor activity, and immune activation of pegylated recombinant human interleukin-10 (AM0010) in patients with advanced solid tumors. J Clin Oncol 34(29):3562–3569PubMedPubMedCentralCrossRef
52.
53.
Coyne GHOS, Conlon K, Takebe N, Streicher H, Quinn MF, Bruns A et al (2018) Phase I study of recombinant interleukin-15 in combination with checkpoint inhibitors nivolumab and ipilimumab in subjects with refractory cancers. J Clin Oncol 36(15_suppl):TPS3128–TPS3TPSCrossRef
54.
Miller JS, Morishima C, McNeel DG, Patel MR, Kohrt HEK, Thompson JA et al (2018) A first-in-human phase I study of subcutaneous outpatient recombinant human IL15 (rhIL15) in adults with advanced solid tumors. Clin Cancer Res 24(7):1525–1535PubMedCrossRef
55.
Francois B, Jeannet R, Daix T, Walton AH, Shotwell MS, Unsinger J et al (2018) Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial. JCI Insight 3(5):e98960PubMedCentralCrossRef
56.
Thomas MG, Bayliss C, Bond S, Dowling F, Galea J, Jairath V et al (2019) Trial summary and protocol for a phase II randomised placebo-controlled double-blinded trial of interleukin 1 blockade in acute severe colitis: the IASO trial. BMJ Open 9(2):e023765PubMedPubMedCentralCrossRef
57.
Zhu J, Huang J, Dai D, Wang X, Gao J, Han W et al (2019) Recombinant human interleukin-1 receptor antagonist treatment protects rats from myocardial ischemia–reperfusion injury. Biomed Pharmacother 111:1–5PubMedCrossRef
58.
Humrich JY, Riemekasten G (2019) Low-dose interleukin-2 therapy for the treatment of systemic lupus erythematosus. Curr Opin Rheumatol 31(2):208–212PubMedCrossRef
59.
Zhang R, Xi X, Wang C, Pan Y, Ge C, Zhang L et al (2018) Therapeutic effects of recombinant human interleukin 2 as adjunctive immunotherapy against tuberculosis: a systematic review and meta-analysis. PLoS One 13(7):e0201025PubMedPubMedCentralCrossRef
60.
Yu K-M, Lau JY-N, Fok M, Yeung Y-K, Fok S-P, Zhang S et al (2018) Preclinical evaluation of the mono-PEGylated recombinant human interleukin-11 in cynomolgus monkeys. Toxicol Appl Pharmacol 342:39–49PubMedCrossRef
61.
62.
Li Q, Sun W, Yuan D, Lv T, Yin J, Cao E et al (2016) Efficacy and safety of recombinant human tumor necrosis factor application for the treatment of malignant pleural effusion caused by lung cancer. Thorac Cancer 7(1):136–139PubMedCrossRef
63.
Foote M (2013) Hematopoietic growth factors. In: Crommelin DJA, Sindelar RD, Meibohm B (eds) Pharmaceutical biotechnology: fundamentals and applications3rd edn. Informa Healthcare, London
64.
Groopman JE, Molina J-M, Scadden DT (1989) Hematopoietic growth factors. N Engl J Med 321(21):1449–1459PubMedCrossRef
65.
Kaushansky K (2006) Lineage-specific hematopoietic growth factors. N Engl J Med 354(19):2034–2045PubMedCrossRef
66.
67.
EMA (2018) Abseamed (epoetin alfa): an overview of Abseamed and why it is authorised in the EU
68.
69.
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
90.
91.
92.
93.
94.
95.
96.
97.
98.
99.
100.
101.
102.
103.
104.
105.
106.
107.
108.
109.
110.
111.
Burchiel SW, Aspbury R, Munday J (2019) The search for biosimilars and biobetters. Drug Discov Today 24:1087–1091PubMedCrossRef
112.
113.
Affentranger L, Bohlius J, Hallal M, Bonadies N (2019) Efficacy of granulocyte colony stimulating factor in combination with erythropoiesis stimulating agents for treatment of anemia in patients with lower risk myelodysplastic syndromes: a systematic review. Crit Rev Oncol Hematol 136:37–47PubMedCrossRef
114.
Hamel S, Kuo V, Sawinski D, Johnson D, Bloom RD, Bleicher M et al (2019) Single center, real-world experience with granulocyte colony-stimulating factor for management of leukopenia following kidney transplantation. Clin Transpl 33:e13541CrossRef
115.
116.
Zhang L, Xu W-H, Fu X-H, Huang Q-X, Guo X-Y, Zhang L et al (2018) Therapeutic role of granulocyte colony-stimulating factor (G-CSF) for infertile women under in vitro fertilization and embryo transfer (IVF-ET) treatment: a meta-analysis. Arch Gynecol Obstet 298(5):861–871PubMedPubMedCentralCrossRef
117.
Herrmann M, Zeiter S, Eberli U, Hildebrand M, Camenisch K, Menzel U et al (2018) Five days granulocyte colony-stimulating factor treatment increases bone formation and reduces gap size of a rat segmental bone defect: a pilot study. Front Bioeng Biotechnol 6:5PubMedPubMedCentralCrossRef
118.
119.
120.
Berlanga J, Férnandez J, López E, López P, del Río A, Valenzuela C et al (2013) Heberprot-P: a novel product for treating advanced diabetic foot ulcer. MEDICC Rev 15(1):11–15PubMedCrossRef
121.
Yamakawa S, Hayashida K (2019) Advances in surgical applications of growth factors for wound healing. Burns Trauma 7(1):10PubMedPubMedCentral
122.
123.
Esquirol-Caussa J, Herrero-Vila E (2019) Human recombinant epidermal growth factor in skin lesions: 77 cases in EPItelizando project. J Dermatol Treat 30(1):96–101CrossRef
124.
Öhnstedt E, Lofton Tomenius H, Vågesjö E, Phillipson M (2019) The discovery and development of topical medicines for wound healing. Expert Opin Drug Discovery 14(5):485–497CrossRef
125.
126.
127.
128.
Sun H, Lu P-P, Zhou P-H, Sun S-W, Zhang H-T, Liu Y-J et al (2017) Recombinant human platelet-derived growth factor-BB versus autologous bone graft in foot and ankle fusion: a systematic review and meta-analysis. Foot Ankle Surg 23(1):32–39PubMedCrossRef
129.
130.
131.
132.
133.
134.
Hanft JR, Pollak RA, Barbul A, van Gils C, Kwon PS, Gray SM et al (2008) Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers. J Wound Care 17(1):30–37PubMedCrossRef
135.
136.
Yeung AWK, Abdel-Daim MM, Abushouk AI, Kadonosono K (2019) A literature analysis on anti-vascular endothelial growth factor therapy (anti-VEGF) using a bibliometric approach. Naunyn Schmiedeberg’s Arch Pharmacol 392(4):393–403CrossRef
137.
Hayes Ryan D, McCarthy FP, O'Donoghue K, Kenny LC (2018) Placental growth factor: a review of literature and future applications. Pregnancy Hypertens 14:260–264PubMedCrossRef
138.
Parchem JG, Brock C, Sibai BM (2019) 442: plasma placental growth factor and the risk of adverse perinatal outcome. Am J Obstet Gynecol 220(1, Suppl):S298CrossRef
139.
140.
Shpichka A, Butnaru D, Bezrukov EA, Sukhanov RB, Atala A, Burdukovskii V et al (2019) Skin tissue regeneration for burn injury. Stem Cell Res Ther 10(1):94PubMedPubMedCentralCrossRef
141.
So K, McGrouther DA, Bush JA, Durani P, Taylor L, Skotny G et al (2011) Avotermin for scar improvement following scar revision surgery: a randomized, double-blind, within-patient, placebo-controlled, phase II clinical trial. Plast Reconstr Surg 128(1):163–172PubMedCrossRef
142.
Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8:915PubMedCrossRef
143.
Key T, Appleby P, Reeves G, Roddam A, Endogenous Hormones and Breast Cancer Collaborative Group (2010) Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol 11(6):530–542PubMedCrossRef
144.
Travis RC, Appleby PN, Martin RM, Holly JM, Albanes D, Black A et al (2016) A meta-analysis of individual participant data reveals an association between circulating levels of IGF-I and prostate cancer risk. Cancer Res 76(8):2288–2300PubMedPubMedCentralCrossRef
145.
Schmidt JA, Allen NE, Almquist M, Franceschi S, Rinaldi S, Tipper SJ et al (2014) Insulin-like growth factor-i and risk of differentiated thyroid carcinoma in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Prev Biomark 23(6):976–985CrossRef
146.
147.
148.
149.
150.
151.
152.
153.
154.
155.
156.
157.
Mesentier-Louro LA, Rosso P, Carito V, Mendez-Otero R, Santiago MF, Rama P et al (2019) Nerve growth factor role on retinal ganglion cell survival and axon regrowth: effects of ocular administration in experimental model of optic nerve injury. Mol Neurobiol 56(2):1056–1069PubMedCrossRef
158.
159.
Aloe L, Rocco ML, Balzamino BO, Micera A (2016) Nerve growth factor: role in growth, differentiation and controlling cancer cell development. J Exp Clin Cancer Res 35(1):116PubMedPubMedCentralCrossRef
160.
Denk F, Bennett DL, McMahon SB (2017) Nerve growth factor and pain mechanisms. Annu Rev Neurosci 40(1):307–325PubMedCrossRef
161.
162.
Metadaten
Titel
Cytokines and Growth Factors
verfasst von
A. C. Silva
J. M. Sousa Lobo
Copyright-Jahr
2020
Verlag
Springer International Publishing
Buch
Current Applications of Pharmaceutical Biotechnology

Print ISBN: 978-3-030-40463-5

Electronic ISBN: 978-3-030-40464-2

Copyright-Jahr: 2020

DOI
https://doi.org/10.1007/10_2019_105

Premium Partner

    Marktübersichten

    Die im Laufe eines Jahres in der „adhäsion“ veröffentlichten Marktübersichten helfen Anwendern verschiedenster Branchen, sich einen gezielten Überblick über Lieferantenangebote zu verschaffen. 

    Zur Marktübersicht
    Bildnachweise